Ming Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ming Liu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Guodong Li
Department of General Surgery, The Fourth-Affiliated Hospital of Harbin Medical University Harbin, China
3 shared publicationsShujun Zhang
Department of Pathology, The Fourth-Affiliated Hospital of Harbin Medical University Harbin, China
3 shared publicationsXin Yu
Department of Internal Medicine, Sino-Singapore Eco-City Hospital of Tianjin Medical University Tianjin, China
3 shared publicationsYichong Wang
The Fourth Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
3 shared publicationsTao Zhang
Department of Orthopedics, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, 150081, China
2 shared publicationsWei Wang
Norwich Medical School, University of East Anglia, Norwich, Norfolk NR4 7UQ, UK
2 shared publications
Latest Publications
- 1 January 2019
- Vol. 12 (3) , 1116
High RASEF expression is associated with a significantly better prognosis in colorectal cancer (vol 11, pg 4276, 2018)
[This corrects the article on p. 4276 in vol. 11, PMID: 31949824.].
- 1 January 2019
- Vol. 12 (3) , 1116
High RASEF expression is associated with a significantly better prognosis in colorectal cancer (vol 11, pg 4276, 2018)
[This corrects the article on p. 4276 in vol. 11, PMID: 31949824.].
- 1 January 2018
- Vol. 11 (9) , 4276-4282
High RASEF expression is associated with a significantly better prognosis in colorectal cancer
This study mainly studied the correlation of RASEF expression and the clinical index of colorectal cancer by tissue microarray (TMAs, HCol-Adel180sur-06) containing tissue samples of 90 colorectal cancers. The results showed that RASEF was significantly highly expressed both in nuclei (3.07 +/- 1.95 vs 1.83 +/- 1.74, P=0.000) and cytoplasm (7.74 +/- 2.08 vs 5.83 +/- 1.97, P=0.000) compared to their para-carcinoma tissues, which was in line with the data of the Oncomine database. The correlation between RASEF expression and microsatellite instability, analyzed by Spearman's correlation analysis showed that RASEF expression in colorectal cancer cytoplasm was correlated significantly with the mismatch repair genes MLH1 (P=0.037; r=0.227) and MSH6 (P=0.038; r=0.224). Additionally, high RASEF expression was associated with a significantly better prognosis (45.3% vs 8%, P=0.041), which was consistent with the data of the Human Protein Atlas. Subsequently, Cox analysis of multi-factor survival showed that RASEF expression was an independent predictive factor for colorectal cancer (P=0.001). Thus, we speculated that RASEF may be a suppressor gene, and may inhibit the development of colorectal cancer through participating in DNA repair processes.
- 1 January 2018
- Vol. 11 (9) , 4276-4282
High RASEF expression is associated with a significantly better prognosis in colorectal cancer
This study mainly studied the correlation of RASEF expression and the clinical index of colorectal cancer by tissue microarray (TMAs, HCol-Adel180sur-06) containing tissue samples of 90 colorectal cancers. The results showed that RASEF was significantly highly expressed both in nuclei (3.07 +/- 1.95 vs 1.83 +/- 1.74, P=0.000) and cytoplasm (7.74 +/- 2.08 vs 5.83 +/- 1.97, P=0.000) compared to their para-carcinoma tissues, which was in line with the data of the Oncomine database. The correlation between RASEF expression and microsatellite instability, analyzed by Spearman's correlation analysis showed that RASEF expression in colorectal cancer cytoplasm was correlated significantly with the mismatch repair genes MLH1 (P=0.037; r=0.227) and MSH6 (P=0.038; r=0.224). Additionally, high RASEF expression was associated with a significantly better prognosis (45.3% vs 8%, P=0.041), which was consistent with the data of the Human Protein Atlas. Subsequently, Cox analysis of multi-factor survival showed that RASEF expression was an independent predictive factor for colorectal cancer (P=0.001). Thus, we speculated that RASEF may be a suppressor gene, and may inhibit the development of colorectal cancer through participating in DNA repair processes.
- Open Access
- 11 April 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 37 (5) , 2905-2912
Differential effects of sulforaphane in regulation of angiogenesis in a co-culture model of endothelial cells and pericytes
Aberrant neovascularization supports nutrients and the oxygen microenvironment in tumour growth, invasion and metastasis. Recapitulation of functional microvascular structures in vitro could provide a platform for the study of vascular conditions. Sulforaphane (SFN), an isothiocyanate, has been reported to possess chemopreventive properties. In the present study, the effects of SFN on cell proliferation and tubular formation have been investigated using endothelial cells (ECs) and pericytes in coculture. SFN showed a dose-dependent inhibition on the growth of ECs and pericytes with IC50 values 46.7 and 32.4 µM, respectively. SFN (5-20 µM) inhibited tube formation in a 3D coculture although a lower dose (1.25 µM) promoted 30% more endothelial tube formation than control. Moreover, SFN affected intercellular communication between ECs and pericytes via inhibition of angiogenic factor such as vascular endothelial growth factor (VEGF) expression in pericytes. However, the expression of its receptor (VEGFR-2) was found significantly increased in ECs. These effects were associated with downregulation of prolyl hydroxylase domain-containing protein 1 and 2 (PHD1/2) and activation of hypoxia-inducible factor-1 (HIF) pathway by SFN. Furthermore, thioredoxin reductase-1 was also upregulated by SFN treatment, suggesting that anti-oxidant and redox regulation are involved in angiogenesis. Taken together, the results of the present study suggest that SFN differentially regulates endothelial cells and pericytes disrupting their interplay through the VEGF-VEGFR signalling pathway. Anti-angiogenesis property of SFN indicates that it has potential role as an anticancer agent.
- 11 April 2017
- Published by Spandidos Publications in Oncology Reports
- Vol. 37 (5) , 2905-2912
Open AccessDifferential effects of sulforaphane in regulation of angiogenesis in a co-culture model of endothelial cells and pericytes
Aberrant neovascularization supports nutrients and the oxygen microenvironment in tumour growth, invasion and metastasis. Recapitulation of functional microvascular structures in vitro could provide a platform for the study of vascular conditions. Sulforaphane (SFN), an isothiocyanate, has been reported to possess chemopreventive properties. In the present study, the effects of SFN on cell proliferation and tubular formation have been investigated using endothelial cells (ECs) and pericytes in coculture. SFN showed a dose-dependent inhibition on the growth of ECs and pericytes with IC50 values 46.7 and 32.4 µM, respectively. SFN (5-20 µM) inhibited tube formation in a 3D coculture although a lower dose (1.25 µM) promoted 30% more endothelial tube formation than control. Moreover, SFN affected intercellular communication between ECs and pericytes via inhibition of angiogenic factor such as vascular endothelial growth factor (VEGF) expression in pericytes. However, the expression of its receptor (VEGFR-2) was found significantly increased in ECs. These effects were associated with downregulation of prolyl hydroxylase domain-containing protein 1 and 2 (PHD1/2) and activation of hypoxia-inducible factor-1 (HIF) pathway by SFN. Furthermore, thioredoxin reductase-1 was also upregulated by SFN treatment, suggesting that anti-oxidant and redox regulation are involved in angiogenesis. Taken together, the results of the present study suggest that SFN differentially regulates endothelial cells and pericytes disrupting their interplay through the VEGF-VEGFR signalling pathway. Anti-angiogenesis property of SFN indicates that it has potential role as an anticancer agent.
- Open Access
- 1 January 2016
- Published by Wiley in Disease Markers
- Vol. 2016, 1-7
Discovery and Validation of Hypermethylated Markers for Colorectal Cancer
Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2andAKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves ofADD2andAKR1B1are higher than that ofSEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation ofADD2andAKR1B1could be potential screening markers of CRC.
- 1 January 2016
- Published by Wiley in Disease Markers
- Vol. 2016, 1-7
Open AccessDiscovery and Validation of Hypermethylated Markers for Colorectal Cancer
Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2andAKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves ofADD2andAKR1B1are higher than that ofSEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation ofADD2andAKR1B1could be potential screening markers of CRC.
- 1 July 2015
- Published by Elsevier in Nutrition Research
- Vol. 35 (7) , 610-617
Synergy between sulforaphane and selenium in protection against oxidative damage in colonic CCD841 cells
- 1 July 2015
- Published by Elsevier in Nutrition Research
- Vol. 35 (7) , 610-617
Synergy between sulforaphane and selenium in protection against oxidative damage in colonic CCD841 cells
- 9 June 2015
- Published by Springer Nature in Tumor Biology
- Vol. 36 (11) , 8781-8787
Overexpression of Wnt7α protein predicts poor survival in patients with colorectal carcinoma
Wnt7α (wingless-type MMTV integration site family, member 7A) is a secreted glycoprotein that plays a critical role in tumorigenesis and development by controlling cell proliferation and differentiation. Whether Wnt7α has the properties of an oncogene or not is an interesting issue because of its diverse expression in different tumors. In the present study, Wnt7α protein expression was evaluated through immunohistochemistry and Western blot analysis. Univariate and multivariate analyses were applied to explore the associations between Wnt7α staining score and various clinical parameters, including overall survival (OS) and disease-free survival (DFS), and a total of 212 patients with colorectal cancer (CRC) were surveyed. Wnt7α was strongly expressed in most CRC tissues but weakly expressed in adjacent normal mucosa, colorectal adenomas, and colonic polyps. High levels of Wnt7α expression were strongly associated with tumor size (P = 0.006), lymph node involvement (P < 0.001), and the international tumor–node–metastasis (TNM) stage (P = 0.005). Patients with strong Wnt7α expression showed significantly poorer OS and DFS than patients with weak Wnt7α expression (P < 0.0001, both). Multivariate Cox analysis confirmed that Wnt7α protein expression and TNM stage are independent factors of adverse OS and DFS in CRC patients. Taken together, our results present evidence that Wnt7α overexpression is associated with an unfavorable prognosis and that positive Wnt7α, in addition to TNM stage, may be an independent prognosis factor influencing OS and DFS prediction in CRC patients.
- 9 June 2015
- Published by Springer Nature in Tumor Biology
- Vol. 36 (11) , 8781-8787
Overexpression of Wnt7α protein predicts poor survival in patients with colorectal carcinoma
Wnt7α (wingless-type MMTV integration site family, member 7A) is a secreted glycoprotein that plays a critical role in tumorigenesis and development by controlling cell proliferation and differentiation. Whether Wnt7α has the properties of an oncogene or not is an interesting issue because of its diverse expression in different tumors. In the present study, Wnt7α protein expression was evaluated through immunohistochemistry and Western blot analysis. Univariate and multivariate analyses were applied to explore the associations between Wnt7α staining score and various clinical parameters, including overall survival (OS) and disease-free survival (DFS), and a total of 212 patients with colorectal cancer (CRC) were surveyed. Wnt7α was strongly expressed in most CRC tissues but weakly expressed in adjacent normal mucosa, colorectal adenomas, and colonic polyps. High levels of Wnt7α expression were strongly associated with tumor size (P = 0.006), lymph node involvement (P < 0.001), and the international tumor–node–metastasis (TNM) stage (P = 0.005). Patients with strong Wnt7α expression showed significantly poorer OS and DFS than patients with weak Wnt7α expression (P < 0.0001, both). Multivariate Cox analysis confirmed that Wnt7α protein expression and TNM stage are independent factors of adverse OS and DFS in CRC patients. Taken together, our results present evidence that Wnt7α overexpression is associated with an unfavorable prognosis and that positive Wnt7α, in addition to TNM stage, may be an independent prognosis factor influencing OS and DFS prediction in CRC patients.
- Open Access
- 15 January 2014
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 15 (1) , 273-276
Ellagic Acid Exerts Anti-proliferation Effects via Modulation of Tgf-Β/Smad3 Signaling in MCF-7 Breast Cancer Cells
Ellagic Acid Exerts Anti-proliferation Effects via Modulation of Tgf-Β/Smad3 Signaling in MCF-7 Breast Cancer Cells Smad3;SIS3;TGF-${\beta}$/Smad3 pathway;ellagic acid;chemoprevention;MCF-7breast cancer cells; Ellagic acid has been shown to inhibit tumor cell growth. However, the underlying molecular mechanisms remain elusive. In this study, our aim was to investigate whether ellagic acid inhibits the proliferation of MCF-7 human breast cancer cells via regulation of the TGF-${\beta}$/Smad3 signaling pathway. MCF-7 breast cancer cells were transfected with pEGFP-C3 or pEGFP-C3/Smad3 plasmids, and treated with ellagic acid alone or in combination with SIS3, a specific inhibitor of Smad3 phosphorylation. Cell proliferation was assessed by MTT assay and the cell cycle was detected by flow cytometry. Moreover, gene expression was detected by RT-PCR, real-time PCR and Western blot analysis. The MTT assay showed that SIS3 attenuated the inhibitory activity of ellagic acid on the proliferation of MCF-7 cells. Flow cytometry revealed that ellagic acid induced G0/G1 cell cycle arrest which was mitigated by SIS3. Moreover, SIS3 reversed the effects of ellagic acid on the expression of downstream targets of the TGF-${\beta}$/Smad3 pathway. In conclusion, ellagic acid leads to decreased phosphorylation of RB proteins mainly through modulation of the TGF-${\beta}$/Smad3 pathway, and thereby inhibits the proliferation of MCF-7 breast cancer cells.
- 15 January 2014
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 15 (1) , 273-276
Open AccessEllagic Acid Exerts Anti-proliferation Effects via Modulation of Tgf-Β/Smad3 Signaling in MCF-7 Breast Cancer Cells
Ellagic Acid Exerts Anti-proliferation Effects via Modulation of Tgf-Β/Smad3 Signaling in MCF-7 Breast Cancer Cells Smad3;SIS3;TGF-${\beta}$/Smad3 pathway;ellagic acid;chemoprevention;MCF-7breast cancer cells; Ellagic acid has been shown to inhibit tumor cell growth. However, the underlying molecular mechanisms remain elusive. In this study, our aim was to investigate whether ellagic acid inhibits the proliferation of MCF-7 human breast cancer cells via regulation of the TGF-${\beta}$/Smad3 signaling pathway. MCF-7 breast cancer cells were transfected with pEGFP-C3 or pEGFP-C3/Smad3 plasmids, and treated with ellagic acid alone or in combination with SIS3, a specific inhibitor of Smad3 phosphorylation. Cell proliferation was assessed by MTT assay and the cell cycle was detected by flow cytometry. Moreover, gene expression was detected by RT-PCR, real-time PCR and Western blot analysis. The MTT assay showed that SIS3 attenuated the inhibitory activity of ellagic acid on the proliferation of MCF-7 cells. Flow cytometry revealed that ellagic acid induced G0/G1 cell cycle arrest which was mitigated by SIS3. Moreover, SIS3 reversed the effects of ellagic acid on the expression of downstream targets of the TGF-${\beta}$/Smad3 pathway. In conclusion, ellagic acid leads to decreased phosphorylation of RB proteins mainly through modulation of the TGF-${\beta}$/Smad3 pathway, and thereby inhibits the proliferation of MCF-7 breast cancer cells.